Cargando…
Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522777/ https://www.ncbi.nlm.nih.gov/pubmed/35920933 http://dx.doi.org/10.1007/s00535-022-01910-7 |
| _version_ | 1784800130867658752 |
|---|---|
| author | Zhou, Qunfang Wang, Xiaohui Li, Ruixia Wang, Chenmeng Wang, Juncheng Xie, Xiaoyan Li, Yali Li, Shaoqiang Mao, Xianhai Liang, Ping |
| author_facet | Zhou, Qunfang Wang, Xiaohui Li, Ruixia Wang, Chenmeng Wang, Juncheng Xie, Xiaoyan Li, Yali Li, Shaoqiang Mao, Xianhai Liang, Ping |
| author_sort | Zhou, Qunfang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9522777 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Nature Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95227772022-10-01 Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis Zhou, Qunfang Wang, Xiaohui Li, Ruixia Wang, Chenmeng Wang, Juncheng Xie, Xiaoyan Li, Yali Li, Shaoqiang Mao, Xianhai Liang, Ping J Gastroenterol Correction Springer Nature Singapore 2022-08-03 2022 /pmc/articles/PMC9522777/ /pubmed/35920933 http://dx.doi.org/10.1007/s00535-022-01910-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Zhou, Qunfang Wang, Xiaohui Li, Ruixia Wang, Chenmeng Wang, Juncheng Xie, Xiaoyan Li, Yali Li, Shaoqiang Mao, Xianhai Liang, Ping Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis |
| title | Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis |
| title_full | Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis |
| title_fullStr | Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis |
| title_full_unstemmed | Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis |
| title_short | Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis |
| title_sort | correction to: sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within milan criteria: a multicenter analysis |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522777/ https://www.ncbi.nlm.nih.gov/pubmed/35920933 http://dx.doi.org/10.1007/s00535-022-01910-7 |
| work_keys_str_mv | AT zhouqunfang correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT wangxiaohui correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT liruixia correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT wangchenmeng correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT wangjuncheng correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT xiexiaoyan correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT liyali correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT lishaoqiang correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT maoxianhai correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis AT liangping correctiontosorafenibasadjuvanttherapyfollowingradiofrequencyablationforrecurrenthepatocellularcarcinomawithinmilancriteriaamulticenteranalysis |